scholarly journals Clinical significance of recurrent copy number aberrations in B-lineage acute lymphoblastic leukaemia without recurrent fusion genes across age cohorts

2017 ◽  
Vol 178 (4) ◽  
pp. 583-587 ◽  
Author(s):  
Monica Messina ◽  
Sabina Chiaretti ◽  
Anna Lucia Fedullo ◽  
Alfonso Piciocchi ◽  
Maria Cristina Puzzolo ◽  
...  
2011 ◽  
Vol 60 (3) ◽  
pp. 375-377 ◽  
Author(s):  
Rodrigo Cayô ◽  
Lucrecia Yañez San Segundo ◽  
Inmaculada Concepción Pérez del Molino Bernal ◽  
Celia García de la Fuente ◽  
Maria Aranzazu Bermúdez Rodríguez ◽  
...  

Acinetobacter junii is a rare human pathogen associated with bacteraemia in neonates and paediatric oncology patients. We present a case of A. junii causing bacteraemia in an adult transplant patient with leukaemia. The correct identification of Acinetobacter species can highlight the clinical significance of the different species of this genus.


2007 ◽  
Vol 136 (2) ◽  
pp. 297-300 ◽  
Author(s):  
Y. Sadakane ◽  
M. Zaitsu ◽  
M. Nishi ◽  
K. Sugita ◽  
S. Mizutani ◽  
...  

2020 ◽  
pp. 5269-5280
Author(s):  
H. Josef Vormoor ◽  
Tobias F. Menne ◽  
Anthony V. Moorman

Acute lymphoblastic leukaemia (ALL) is a malignant proliferation of lymphoid blasts, most commonly of B-lineage origin. The clinical symptoms and signs are either a consequence of bone marrow failure (infections, bruising, petechiae, pallor, and tiredness) or a consequence of the uncontrolled proliferation of the blasts (lymphadenopathy, hepatosplenomegaly, and cranial nerve palsies). Its peak incidence is in young children but ALL occurs at all ages. More than 80% of all affected children are cured with modern chemotherapy, but unfortunately the outcome of adults is much worse despite some improvements led by the introduction of paediatric-inspired protocols and tyrosine kinase inhibitors in BCR-ABL1-positive ALL. Standard chemotherapy for ALL consists of several months of intensive multidrug induction, consolidation and intensification chemotherapy (including steroids, vincristine, asparaginase and anthracyclines), intrathecal methotrexate to target blasts in the central nervous system, and low-intensity maintenance therapy (with oral 6-mercaptopurine and methotrexate) for up to 3 years. Treatment is stratified according to the response and other prognostic biomarkers (including genetics). Allogeneic haematopoietic stem cell transplantation is used predominantly in the relapse setting for children but in frontline therapy for adult patients to consolidate chemotherapy. Novel targeted small molecules and, in particular, immunotherapy are promising to offer new treatment options for patients with high-risk or relapsed disease.


1996 ◽  
Vol 93 (1) ◽  
pp. 125-130 ◽  
Author(s):  
Frans J. Smiers ◽  
Marleen van Paassen ◽  
Karel Hählen ◽  
Bob Löwenberg ◽  
Ivo P. Touw

Sign in / Sign up

Export Citation Format

Share Document